Published in J Pathol on January 01, 2006
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.91
Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Effective lay health worker outreach and media-based education for promoting cervical cancer screening among Vietnamese American women. Am J Public Health (2007) 1.92
Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer (2007) 1.32
Gene expression changes during HPV-mediated carcinogenesis: a comparison between an in vitro cell model and cervical cancer. Int J Cancer (2008) 1.21
Multiplex Identification of Human Papillomavirus 16 DNA Integration Sites in Cervical Carcinomas. PLoS One (2013) 1.19
Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer (2008) 1.11
Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol (2006) 1.11
HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol (2011) 1.10
Distribution of Human Papillomavirus Genotypes among HIV-Positive and HIV-Negative Women in Cape Town, South Africa. Front Oncol (2014) 1.08
Controversies surrounding human papilloma virus infection, head & neck vs oral cancer, implications for prophylaxis and treatment. Head Neck Oncol (2009) 1.04
Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests. Cancer (2008) 1.00
Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract. Proteome Sci (2010) 0.96
Prognostic value of DNA and mRNA e6/e7 of human papillomavirus in the evolution of cervical intraepithelial neoplasia grade 2. Biomark Insights (2014) 0.93
Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer. J Exp Clin Cancer Res (2012) 0.92
Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens. J Mol Diagn (2007) 0.92
Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis. PLoS One (2014) 0.90
MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer (2014) 0.89
Prevalence of human papilloma virus infection in women in rural Ethiopia. Eur J Epidemiol (2006) 0.88
CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women. BMC Cancer (2010) 0.87
Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers. Cancer Gene Ther (2010) 0.87
Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell Int (2006) 0.85
Differential in vitro immortalization capacity of eleven (probable) [corrected] high-risk human papillomavirus types. J Virol (2013) 0.85
Papillomas of the external ear canal: report of ten cases in Chinese patients with HPV in situ hybridization. Head Neck Pathol (2009) 0.84
Adaptive evolution of a stress response protein. PLoS One (2007) 0.84
Human papillomavirus (HPV) related carcinomas of the upper aerodigestive tract. Head Neck Pathol (2007) 0.83
Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol (2015) 0.82
HPV infection and cervical neoplasia: associated risk factors. Infect Agent Cancer (2015) 0.82
Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid. PLoS One (2014) 0.82
Laboratory and clinical aspects of human papillomavirus testing. Crit Rev Clin Lab Sci (2012) 0.80
Association between human papillomavirus and human T-lymphotropic virus in indigenous women from the Peruvian Amazon. PLoS One (2012) 0.80
Point-of-care test for cervical cancer in LMICs. Oncotarget (2016) 0.80
Virus transcript levels and cell growth rates after naturally occurring HPV16 integration events in basal cervical keratinocytes. J Pathol (2014) 0.80
Natural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literature. BMC Pregnancy Childbirth (2016) 0.80
HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia. BMC Cancer (2012) 0.79
Green and black tea in relation to gynecologic cancers. Mol Nutr Food Res (2011) 0.79
Low- and high-risk human papillomavirus E7 proteins regulate p130 differently. Virology (2010) 0.79
Direct human papillomavirus E6 whole-cell enzyme-linked immunosorbent assay for objective measurement of E6 oncoproteins in cytology samples. Clin Vaccine Immunol (2012) 0.79
The ecology of human papillomavirus-induced epithelial lesions and the role of somatic evolution in their progression. J Infect Dis (2013) 0.78
[HPV-associated squamous cell carcinogenesis]. Pathologe (2011) 0.78
Aberrant expression of microRNA-26b and its prognostic potential in human cervical cancer. Int J Clin Exp Pathol (2015) 0.78
The human papillomavirus E7 proteins associate with p190RhoGAP and alter its function. J Virol (2014) 0.78
Methylation of Cervical Neoplastic Cells Infected With Human Papillomavirus 16. Int J Gynecol Cancer (2016) 0.77
Substantial increase in the frequency of circulating CD4+NKG2D+ T cells in patients with cervical intraepithelial neoplasia grade 1. J Biomed Sci (2013) 0.77
The LKB1 tumor suppressor differentially affects anchorage independent growth of HPV positive cervical cancer cell lines. Virology (2013) 0.77
HPV 16 Is Related to the Progression of Cervical Intraepithelial Neoplasia Grade 2: A Case Series. Obstet Gynecol Int (2013) 0.77
Human papillomavirus-16 associated adenocarcinoma NOS of base of tongue. Head Neck Pathol (2012) 0.77
[Human papillomavirus infection. Pathology and molecular pathology]. Pathologe (2008) 0.76
Lethality of PAK3 and SGK2 shRNAs to human papillomavirus positive cervical cancer cells is independent of PAK3 and SGK2 knockdown. PLoS One (2015) 0.76
Expression of E6, p53 and p21 proteins and physical state of HPV16 in cervical cytologies with and without low grade lesions. Int J Clin Exp Med (2014) 0.76
Different effects of H2O2 treatment on cervical squamous carcinoma cells and adenocarcinoma cells. Arch Med Sci (2015) 0.75
Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence. BMC Infect Dis (2015) 0.75
The prognostic value of squamous cell carcinoma antigen for predicting tumor recurrence in cervical squamous cell carcinoma patients. Obstet Gynecol Sci (2015) 0.75
Human papillomavirus-associated adenocarcinoma of the base of tongue: potentially actionable genetic changes. Head Neck Pathol (2013) 0.75
Transcriptomic analyses of genes differentially expressed by high-risk and low-risk human papilloma virus E6 oncoproteins. Virusdisease (2015) 0.75
Bax and Bak expression in cervical smears of women with low-and high-risk HPV types: A study of 120 cases. J Cytol (2016) 0.75
Association between folate status and cervical intraepithelial neoplasia. Eur J Clin Nutr (2016) 0.75
FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women. Br J Cancer (2016) 0.75
Genomic Copy Number Variations Characterize the Prognosis of Both P16-Positive and P16-Negative Oropharyngeal Squamous Cell Carcinoma After Curative Resection. Medicine (Baltimore) (2015) 0.75
Human genomic diversity, viral genomics and proteomics, as exemplified by human papillomaviruses and H5N1 influenza viruses. Hum Genomics (2009) 0.75
Differential proteins among normal cervix cells and cervical cancer cells with HPV-16 infection, through mass spectrometry-based Proteomics (2D-DIGE) in women from Southern México. Proteome Sci (2016) 0.75
Promoter methylation status of the tumor suppressor genes p16 and cadherin 1 in cervical intraepithelial neoplasia. Oncol Lett (2017) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol (2002) 5.63
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine (2008) 4.82
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 3.67
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol (2011) 3.58
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine (2006) 3.15
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine (2012) 3.09
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood (2007) 2.82
Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst (2002) 2.75
Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol (2011) 2.52
Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis (2005) 2.20
Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol (2006) 2.20
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ (2010) 2.10
The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis (2005) 2.07
The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol (2003) 2.04
Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol (2008) 2.00
Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control (2003) 2.00
Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer (2002) 1.98
Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol (2003) 1.96
Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis (2003) 1.93
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia (2004) 1.92
The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res (2009) 1.87
Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev (2010) 1.85
Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol (2008) 1.78
Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.77
Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int J Cancer (2003) 1.77
Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer (2003) 1.74
Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses. Int J Epidemiol (2004) 1.73
High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer (2012) 1.71
Human papillomavirus infection among women in South and North Vietnam. Int J Cancer (2003) 1.71
Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev (2005) 1.71
Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer (2003) 1.71
Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer (2010) 1.69
EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol (2004) 1.68
Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer (2004) 1.62
The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Int J STD AIDS (2002) 1.60
HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol (2006) 1.59
Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol (2003) 1.58
Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer (2011) 1.57
Flat penile lesions: the infectious "invisible" link in the transmission of human papillomavirus. Int J Cancer (2006) 1.56
Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer (2006) 1.56
Clonal selection for transcriptionally active viral oncogenes during progression to cancer. J Virol (2004) 1.56
HPV-mediated transformation of the anogenital tract. J Clin Virol (2005) 1.55
Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer (2005) 1.55
Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev (2004) 1.54
Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol (2007) 1.53
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol (2005) 1.51
Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res (2011) 1.50
Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol (2002) 1.49
Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis (2003) 1.47
Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev (2013) 1.47
Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear. Cancer Epidemiol Biomarkers Prev (2006) 1.47
TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst (2004) 1.45
Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer (2007) 1.45
Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. J Infect Dis (2010) 1.41
Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer (2005) 1.40
Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med (2013) 1.40
Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. Int J Cancer (2008) 1.39
Enteropathy associated T-cell lymphoma and its precursor lesions. Best Pract Res Clin Gastroenterol (2010) 1.39
Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer (2007) 1.37
Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.34
Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia (2005) 1.34
Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies. J Clin Microbiol (2002) 1.34
Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol (2011) 1.34
Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer (2011) 1.34
Combination of PCR targeting the VD2 of omp1 and reverse line blot analysis for typing of urogenital Chlamydia trachomatis serovars in cervical scrape specimens. J Clin Microbiol (2004) 1.33
Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood (2003) 1.33
Prevalence of human papillomavirus infection among women in Concordia, Argentina: a population-based study. Sex Transm Dis (2003) 1.33
Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer (2012) 1.31
CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer (2007) 1.31
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res (2010) 1.29
Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev (2008) 1.29
Human papillomavirus detection by penile site in young men from Kenya. Sex Transm Dis (2007) 1.28